Our purpose was to compare HDL subpopulations, as determined by non-denaturing two-dimensional gel-electrophoresis followed by immunoblotting for apolipoproteins A-I, A-II, A-IV, Cs, and E, in heterozygous, compound heterozygous, and homozygous subjects for CETPdeficiency and controls. Heterozygotes, compound heterozygotes, and homozygotes had CETP mass that were 30%, 63%, and over 90% lower, and HDL-C values that were 64%, 168%, and 203% higher than in controls, respectively. Heterozygotes had about 50% lower preβ-1 and more than two-fold higher levels of α-1 and preα-1 particles than controls. Three out of the five heterozygotes' α-1 particles also contained apoA-II, which was not seen in controls. Compound heterozygotes and homozygotes had very large particles not observed in controls and heterozygotes. These particles contained apoA-I, apoA-II, apoCs, and apoE. However, these subjects did not have decreased preβ-1 levels. Our data indicate that CETP deficiency results in the formation of very large HDL particles containing all the major HDL apolipoproteins except for apoA-IV. We hypothesize that the HDL subpopulation profile of heterozygous CETPdeficient patients, especially those with high LpA-I α-1 levels, represent an improved antiatherogenic state, while this might not be the case for compound heterozygotes and homozygotes with very large, undifferentiated HDL particles.
Introduction
Cholesteryl ester transfer protein (CETP) is a 74 KD hydrophobic glycoprotein bound mainly to HDL. CETP catalyzes the equilibrium of non-polar lipids (triglyceride [TG] and cholesteryl ester [CE] ) between plasma lipoprotein particles (1, 2). The major role of CETP is a net transfer of CE from HDL to triglyceride-rich lipoproteins (TRL) and of LDL and TG from TRL to LDL and HDL. CETP mRNA is expressed in several tissues, but the majority of circulating CETP originates from the liver (3).
CETP plays a key role in HDL metabolism (4) . It regulates total plasma HDL-C level and also facilitates the remodeling of HDL particles (5) . A high CETP concentration correlates with a low HDL-C level, a strong risk factor for coronary artery disease (6) . On the other hand, Asian subjects with CETP deficiency have markedly elevated HDL-C (three to six-fold) and apoA-I concentrations (7) (8) (9) . CETP-deficiency induced elevation in HDL-C level is mainly found in the large HDL2 subclass. Moreover, the average HDL size of CETP deficient subjects is significantly increased and enriched in cholesterol (10) . These large HDL particles have been reported to be less effective in promoting cholesterol efflux from lipid-loaded macrophages than HDL particles of control subjects (11) .
Several mutations of the CETP gene have been identified as causes of CETP-deficiency and elevated HDL-C levels. These include a G to A substitution within intron 14 at the donor splice site (Int14A), a mutation that is present in up to 2% of the total Japanese population and in as many as 27% of people in the Omagari area of Japan, as well as a missence mutation in exon 15 (D422G) present in up to 7% of the Japanese population (12) (13) (14) (15) (16) . Inazu et al. reported that heterozygous CETP-deficiency caused by the Int14A mutation was potentially anti-atherogenic by guest, on www.jlr.org Downloaded from and might be associated with an increased life span (9) . Hirano et al. found no correlation between CETP deficiency and longevity. They published a U-shape correlation curve between HDL-C and the incidence of ischemic electrocardiogram changes indicating that both low and high HDL-C levels can be atherogenic (16) . Hirano and others speculated that alcohol intake might modify the atherogenicity of some CETP polymorphisms since it decreases CETP levels (17, 18) . Recently Barter et al. summarized these finding in a review article (19) .
In the present study, we investigated the size and apolipoprotein composition of HDL, separated by two-dimensional non-denaturing gel-electrophoresis (2dE), from the plasma of nine homozygous, four compound heterozygous, and five heterozygous subjects with CETPdeficiency, and compared them to fifty age and gender matched controls.
Methods:

Study population
Plasma samples were obtained from subjects with genetic CETP-deficiency and compared to healthy controls. We studied nine subjects (3 males and 6 females) homozygous for the mutation involving intron 14 (G (+1)-to-A transition (Int14A) resulting in the null phenotype, four compound heterozygotes (2 males and 2 females) with the same Int14A plus one missense mutation of D442G in exon 15, resulting in a defective phenotype with a potentially dominant negative effect, and five heterozygotes (3 males and 2 females), two with the Int14A and three with the D442G mutation. The control group was composed of 25 healthy male and 25 healthy female subjects of similar age. Table 1 contains data about age, gender, and biochemical parameters of the subjects studied. None of the subjects were on medication known for altering by guest, on www.jlr.org Downloaded from lipid levels. All participants of the study gave a written informed consent. The study protocol was approved by Kanazawa University.
Blood was collected from subjects after an overnight fast into EDTA tubes, and centrifuged at low speed at 4˚C for 20 min to obtain plasma. Plasma was aliquoted and stored at -80˚C. To further protect lipoprotein particles from degradation, plasma aliquots were thawed fast (1-2 min) in a 37˚C water bath and put on ice until use. Samples were stored and handled the same way for control and CETP-deficient subjects. We did not notice any signs of sample degradation due to sample handling or storage in this study. It is worth noting here that the 2dE, immunoblot, image analysis method is sensitive and indicative for depicting degraded samples due to the fact that degraded plasma samples show a distinct pattern visible on the 2d electrophoretogram.
Lipid, Apolipoprotein, and CETP Measurements
Total-C, HDL-C, and TG were measured by automated enzymatic assays using a Hitachi 911 analyzer and kits from Roche Diagnostics (Indianapolis, IN). LDL-C was calculated by the Friedewald formula. Phospholipids and free cholesterol were measured by automated enzymatic assays using kits from Wako Diagnostics (Richmond, VA). Cholesteryl ester was calculated by deducting free cholesterol from total cholesterol. ApoA-I and apoA-II were assayed immunoturbidimetricly using Wako kits. LpA-I was measured by rocket electrophoresis, using crosselectrophoresis kits from Sebia (Norcross, GA). LpA-I:A-II was calculated by deducting LpA-I from plasma total apoA-I. CETP mass was measured by ELISA kits from Wako. ApoA-IV, apoC-I, apoC-II, apoC-III, and apoE were determined by dot-blot analyses and their concentrations were expressed as percentile of controls. Between-run coefficients of variation for all assays were <10%.
HDL Subpopulation Analysis
Two-dimensional non-denaturing agarose-polyacrylamide gel-electrophoresis and image analysis for determining the apoA-I-containing HDL subpopulations were carried out on plasma previously stored at -80°C, as described (20, 21) . Briefly, in the first dimension, HDL particles were separated on agarose gel according to charge. This separation identified 3 fractions, referred to as preβ, α, and preα particles, on the basis of mobility relative to albumin. Low endosmosity 0.7% agarose was cast into 3mm thick vertical glass cassettes and electrophoresed in a Pharmacia GE 2/4 re-circulating apparatus. Four µl of plasma per sample channel were electrophoresed at constant voltage (250 V) and temperature (10°C) in tris-tricine buffer until the endogenous albumin, stained with bromophenol blue, moved 3.5 cm from the origin. Individual strips were cut out and transferred to the top of non-denaturing concave-gradient (3-35%) polyacrylamide gels and particles were further separated according to size. Electrophoresis was performed to completion in tris-borate buffer at constant voltage (250 V) and temperature (10°C) for 24 hrs. Gels were electro-transferred to nitrocellulose membranes at constant voltage (30V) and temperature (10°C) for 24 hrs in tris-glycine buffer.
Prior to immunoblotting, membranes were fixed with 0.03% glutaraldehyde and the free protein binding capacity was blocked by incubating membranes in PBS containing 0.05% Tween (PBST) and 5% nonfat dry milk. ApoA-I was immunolocalized by incubation with PBST containing 5% milk and monospecific goat human apoA-I antibody for 7 hrs followed by IV, C-I, C-II, C-III, and E, as described above with primary antibodies specific for these apolipoproteins and 125 I-labeled secondary antibody. Signals were quantitatively determined by image analysis using a FluoroImager in X-ray mode for the 125 I label and in red-fluorescent mode for the Cy5 label.
The subpopulations were determined both as percent distribution and concentration relative to apoA-I. Preβ-1 and preβ-2 particles did not overlap with any other HDL particles so they were easily delineated. Designation of the α-mobility HDL subpopulations was based on integration of α-migrating HDL. We delineated each peak area shown on the integration curve, for the α-mobility particles. Preα-mobility particles had similar sizes to their α-mobility counterparts and were clearly separated from each other. Finally, all apoA-I-containing HDL subpopulations were encircled (we pooled the two preβ-1 particles into one and also the three preβ-2 particles into one subpopulation), signals were measured in each area and used for calculating the percent distribution of the apoA-I-containing HDL subpopulations. Data were expressed as pixels linearly correlated with the disintegrations per minute of the 125 I bound to the antigen-antibody complex (22) . ApoA-I concentrations of the subpopulations were calculated by multiplying percentiles of subfractions by plasma total apoA-I concentrations. We had a CV of <10% for all of the α-mobility subpopulations and < 15% for the rest of the particles.
Statistical Analysis:
Analysis of variance (ANOVA) was used to test the hypothesis of no difference between data obtained from control and affected subjects. A P value of <0.05 was considered as significant.
For analysis, non-normally distributed data were logarithmically transformed.
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Results: Table 1 shows the plasma biochemical parameters of the four groups: homozygotes (HO), compound heterozygotes (CH), heterozygotes (HE), and controls. Subjects with either mutation had significantly lower levels of CETP mass: HO <0.1µg/ml, CH 0.46 µg/ml, and HE 0.87 µg/ml compared to controls (1.24µg/ml). The nine HOs had elevated total cholesterol levels (44%) but normal free to esterified cholesterol ratios. They had slightly decreased LDL-C (-14%) and TG (-13%) levels while their mean HDL-C level was three-fold higher than the mean control value. Homozygotes had 75% higher apoA-I and 13% higher apoA-II concentrations than controls. The differences between CHs and controls were very similar to differences described for HOs and controls. Compared to controls, HEs had 35% and 27% lower LDL-C and TG, and 64% higher HDL-C, respectively, with no notable differences for apoA-I and apoA-II. In all affected groups, the LpA-I fraction was elevated to about the same extent as that of LpA-I:A-II.
The apoA-I containing HDL subpopulations are expressed both as percent distribution and as absolute concentrations (mg/dl) in Tables 2a and 2b . We detected two extra, large α-mobility particles (and) in HO and CH subjects with a mean size of 12.9 nm (α-L) and 16.6 nm (α-VL) (Figure 1) . Adjacent to the α-L and α-VL particles, there were preα mobility particles with similar sizes. These very large α and preα particles were not present in any of the control or HE subjects. In homozygotes, the percentiles of the α-L, preα-L, α-VL and preα-VL were 24.7% and 4.6%, 18.9% and 1.4%, respectively. The normal-size α-1 was 17% lower, while the normal-size preα-1 was 23% higher than these percentiles in controls. The percentiles of α-2, α-3, as well as the adjacent preα-2 and preα-3, were 72%, 75%, 69% and 73% lower, respectively, in HOs than in controls. Moreover, a new, small particle, similar in size to preβ-1 HDL but with faster mobility, was detected in HO subjects. We denoted this particle as fast preβ-1 (preβ-1F).
Among the compound heterozygotes only one subject had α-VL particles, but all of them had α-L particles and their major HDL particle was the regular size α-1. Heterozygotes had no HDL fraction what was not present in controls. They had more than two-fold higher percentiles of α-1
and preα-1 than controls. The percentiles of α-2, α-3, the adjacent preα-2, preα-3 particles, and the smallest particle, preβ-1, were markedly lower by 15%, 43%, 29%, 35%, and 43%, respectively, in HEs compared to controls.
Absolute concentrations were calculated by multiplying plasma apoA-I concentrations with the percentiles of HDL subspecies ( Table 2b ). The elevated total apoA-I concentrations (75%, 56%, and 7% in the HO, CH, and HE groups compared to controls) further enhanced the differences among affected and control subjects in terms of the large HDL particles. ApoA-I concentrations in HDL particles with similar or larger size than normal-size α-1 (>11. We also compared plasma total apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, and apoE concentrations and their distribution and mass within the HDL subpopulations, as determined by immunoblotting for these apolipoproteins, among the four groups. Compared to controls, apoA-II was slightly increased in CH (18%) and HO (13%) subjects and was similar in HEs. ApoA-II was present in the α-2 and α-3 subpopulations of controls, while, in affected subjects, apoA-II was present in all α-mobility HDL subpopulations ( Table 3 and Figure 2 ). In HOs, apoA-II was by guest, on www.jlr.org
Downloaded from also present in the fast preβ-1 particle. In affected subjects, the apoA-I/A-II ratio increased in all LpA-I:A-II subpopulations compared to controls due to a disproportional increase of total apoA-I to total apoA-II and also due to a disproportional displacement of these proteins into the larger size particles (Table 4) .
When we determined the apoA-IV profile, we found that neither the concentration nor the percent distribution and localization of the apoA-IV-containing particles were different between affected and control subjects.
Plasma apoC-I concentration was higher by 13% in HE, 23% in CH, and 34% in HO subjects compared to controls. In control subjects, apoC-I was present in the three α-mobility HDL particles with large individual variability in the percent distributions. In HE and CH subjects, apoC-I was present predominantly in the α-1 subpopulation, while in homozygotes 95% of apoC-I was in the three large α-mobility particles (α-1, α-L, and α-VL).
ApoC-II concentration in plasma was lower by 23% and 10% in HE and CH subjects, respectively, while it was 18% higher in HO subjects than in controls. The distribution of apoC-II in controls and affected subjects was very similar to that of apoC-I in these subjects.
Plasma apoC-III concentration was 13% lower in HEs and was similar in CHs compared to controls. Despite a 50% higher apoC-III level in three of the HO subjects, the mean concentration of apoC-III in the nine HOs was only 11% higher than in controls. In control subjects, apoC-III was present in the α-2 and α-3 particles and in a small preβ-mobility particle.
ApoC-III distribution in HE and control subjects were similar, however, in HOs and CHs, the majority of apoC-III was in the three largest α-mobility particles contrary to controls. In the HO and CH groups, some apoC-III was also detected in a small α-mobility particle (similar in size to the preβ-mobility apoC-III in controls).
ApoE concentration was elevated in all three affected groups by 16%, 38%, and 43% in HE, CH, and HO subjects, respectively compared to the control group. ApoE did not co-migrate with apoA-I in control subjects, however, it co-migrated with apoA-I in the three largest α-mobility particles (α-1, α-L, α-VL) of all affected subjects but most markedly in homozygotes (Figure 3) .
Discussion:
Cholesteryl ester transfer protein plays an important role in HDL metabolism by facilitating the transfer of cholesteryl ester to apoB-containing lipoproteins in partial exchange for triglyceride. Significant interest in CETP has been generated by the description of Japanese subjects heterozygous and homozygous for CETP-deficiency with very high levels of HDL-C. It has previously been shown that CETP-deficiency is associated with marked increases in large HDL or HDL2, and that homozygotes have marked apoE enrichment in this fraction (7, 9, 23) .
It has also been reported that statin treatment not only modestly increases HDL-C but also causes a significant increase in large HDL particles (24, 25) due, at least in part, to decreased CETP activity (26) . Pharmaceutical companies have had great interest in developing small molecules to raise HDL-C and decrease CHD risk. For this reason, a number of companies have developed CETP inhibitors. One of these agents has been reported to decrease diet-induced atherosclerosis in animals as well as significantly increase HDL-C in these animals as well as in humans (27, 28 ).
The 2dE method followed by immunoblotting and image-analysis allows for the precise delineation of specific HDL subspecies and provides metabolic information as it separates intermediates (lipid-poor, discoidal, and spheroidal fractions) representing the main stages of HDL synthesis. Using this methodology, we have reported the presence of 12 apoA-I containing HDL subspecies in human plasma (20) . The largest α-mobility HDL particle, α-1, resembles HDL-2 separated by ultracentrifugation (29) . In control subjects, only α-2 and α-3 HDL particles contain apoA-II, the rest are apoA-I only particles (21 We have documented that patients with CHD have marked decreases in α-1 and preα-1 HDL, and that statins can increase both α-1 and preα-1 HDL levels significantly (24, 25, 29) .
More recently we have reported that simvastatin-niacin treatment in the HDL Atherosclerosis Treatment Study markedly increased both α-1 and preα-1 HDL and that subjects with the greatest increases in α-1 had no progression of coronary artery stenosis, in contrast to other subjects (31) . Based on these data, we believe that the large LpA-I α-1 is an anti-atherogenic HDL particle.
In the present study, we document the presence of novel apoA-I-containing particles in patients with CETP-deficiency. We confirm previous observations that subjects with heterozygous CETP-deficiency have increased HDL-C level and size. In these subjects, a 30% decrease in CETP mass resulted in a marked alteration in the HDL particle distribution. Most notably, there was an increase in the large α-1 and preα-1 particles and a decrease in the small preβ-1 particle. The unique finding was that three of the five HEs had apoA-II in α-1 HDL, which was an LpA-I particle in controls.
As expected, the magnitude of the HDL alterations observed in HEs was significantly amplified in CHs and HOs with 63% lower and no detectable CETP masses, respectively. These subjects not only had marked increases in α-1 HDL but also the appearance of larger than normal α-and preα-mobility HDL particles not observed in controls and HEs. The α-mobility particles contained apoA-II besides apoA-I but -possibly even more significantly -contained other apolipoproteins, specifically apoE, apoC-III, apoC-II, and apoC-I in order of decreasing abundance. It has to be noted that co-migration of different apolipoproteins generally does not mean that these proteins are in the same particle. However, co-migration of different apolipoproteins in a two-dimensional system significantly increases the probability of being in the same particle.
Our data is in agreement with earlier observations that subjects homozygous for CETPdeficiency have HDL particles containing apoA-I, apoA-II, and apoE and also with reports that apoE resides mainly in the large HDL particles (8, 32, 33) . It has been reported that HDL particles enriched in apoA-II and apoE have a decreased capacity for efflux of cholesterol from macrophages (11) and that the plasma residence time of apoE is about ten times longer if apoE is present in LpE:A-II:A-I particles (34).
It is hard to speculate about the interaction of these undifferentiated, large particles with the HDL modifying enzymes and CETP, in light of the fact that all three C apolipoproteins are present in these particles. ApoC-I and apoC-III inhibit lipoprotein lipase (LPL) activity while apoC-II activates LPL. Both apoC-II and apoC-III reduce hepatic lipase (HL) activity while apoC-I has no effect on it. On the other hand, apoC-I activates lecithin:cholesterol acyltransferase (LCAT), while the other two apoCs inhibit LCAT. ApoC-I reduces and apoC-III increases cholesteryl ester transfer by CETP. Recently, Jong et al. summarized the influence of apoCs on these factors (35) . It would be interesting to know how these large lipid-rich particles (α-1, α-L, α-VL) influence the distribution of apoC-III between the HDL and TRL fractions, since non-HDL apoC-III is a CHD-risk factor. The precise role of these particles in promoting cholesterol efflux remains to be determined.
In contrast to HEs, CHs and HOs had significantly increased concentration of preβ-1 particles. We assume that the observed increase in preβ-1 level was not due to lower LCAT activity since the plasma FC/CE ratios of CETP-deficient subjects were not different from controls. The increased preβ-1 level was not the result of higher HL activity either because HL produces small α-mobility particles besides preβ-1, but those particles were significantly lower in CETP-deficient subjects. We postulate that the higher than normal preβ-1 levels in these subjects were the result of increased phospholipids transfer protein (PLTP) activity based on reports that PLTP produces preβ-1 and large HDL-2-like particles (36) .
Our data strongly indicate that CETP plays a significant role in modulating HDL metabolism affecting HDL-C level and the distribution, size, and apolipoprotein composition of HDL particles. Our studies suggest that CETP-deficiency not only causes the appearance of very large HDL particles, but also causes the apoA-I in these particles to associate initially with apoA-II, and then with all of the other HDL apolipoproteins except for apoA-IV. Consequently, CETP is essential for the formation of heterogeneous HDL not only in size but also in apolipoprotein composition.
In agreement with others, we postulate that HDL particles with altered apolipoprotein composition in HOs and CHs, may not be as efficient as regular HDL particles in promoting reverse cholesterol transport. We believe that the LpA-I:A-II HDL particles have lesser capability to promote SR-B1-mediated cholesterol uptake in the liver than LpA-I HDL. This issue was recently reviewed by Fidge and debated by deBeer (37, 38) .
On the other hand, we assume that HEs with significantly increased apoA-I but not apoA-II in α-1 HDL particles along with the significantly decreased α-3 and preβ-1 levels mark an effective reverse cholesterol transport. In addition, HEs subjects have very low LDL-C levels probably due to decreased lipid exchange between LDL and HDL resulting in small CE-poor but TG-rich LDL particles. In complete CETP deficiency in humans, the cholesterol esters of VLDL and its catabolic product, LDL, originate predominantly from intracellular acyl-CoA:cholesterol acyltransferase (39) .
Considering this information, we assume that the HDL subpopulation profile of heterozygous CETP-deficient patients, especially those with high LpA-I α-1 levels, represent an improved anti-atherogenic state, while this might not be the case for compound heterozygotes and homozygotes with very large, undifferentiated HDL particles. 
